The research follows a KFF Health Tracking Poll in May in which 12% of adults reported taking a GLP-1 drug at some point. Six percent said they are currently using one. There are a variety of GLP ...

Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction of the cost of brand-name competitors such as Wegovy and Ozempic.

Popular weight-loss drugs mimic GLP-1, a hormone the body makes naturally after eating. Turns out some foods trigger GLP-1 better than others, making us feel full and eat less.

People using GLP-1 medications aren’t just ‘taking the easy way out.’ You’ve probably seen someone online make the accusation, so-and-so lost weight, they must be taking Ozempic — cheater.

MariTide has a 21-day half-life —that’s three times as long as the once-weekly GLP-1 drugs currently approved by the FDA. As such, it can potentially be taken monthly, or perhaps every three ...

People who stop taking GLP-1 medications like Wegovy and Zepbound started to regain weight in a short amount of time, a new study suggests. Researchers analyzed 11 different studies to understand ...

Topline The use of GLP-1 medications like semaglutide for weight loss has increased twofold over the past decade, but declined in use among those with type 2 diabetes, according to a new study ...

A comprehensive new study confirmed that GLP-1 medications such as Ozempic and Mounjaro have myriad health benefits — even more than previously thought. Analyzing the medical records of roughly ...

GLP-1s impact the GI tract, reduce birth control efficacy GLP-1s induce weight loss by slowing down the gastrointestinal (GI) tract, also known as the digestive tract, according to Miller.

GLP-1 drugs may protect the brain from inflammation, some studies say, but others warn they may increase depression risk. Image credit: James Manning – PA Images/Getty Images.

GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase.

People on GLP-1s who have developed a sudden aversion to steak, burgers and chicken are calling their newfound disgust the "meat ick." (Getty Images) Merris Taylor has never loved a fatty ribeye ...